A2A

A2A NEWSROOM (1 press releases)

Advanced Filtering & Sorting Options:

Archive by Year: All 2025 2024 2023 2022 2018 2016 2014 2013 2012

Biotie’s tozadenant (SYN115) meets primary and multiple secondary endpoints in phase 2b study in Parkinson’s disease

PRESS RELEASE -- 18, December 2012

18-12-2012 — /europawire.eu/ — Biotie today reported top-line data from a Phase 2b study evaluating its adenosine A2a antagonist tozadenant (SYN115) in Parkinson’s disease (PD) patients experiencing levodopa related end of dose wearing off. The study met its primary endpoint of … Read the full press release